New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)

Systemic lupus erythematosus (SLE) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by overproduction of organ-specific autoantibodies to various components of the cell nucleus and the development of immune-inflammatory damage to internal organs. According to modern conc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: E. L. Nasonov, A. S. Avdeeva, T. V. Popkova
Natura: Artigo
Lingua:Russo
Pubblicazione: IMA-PRESS LLC 2021-10-01
Serie:Научно-практическая ревматология
Soggetti:
systemic lupus erythematosus
interferon
genetically engineered biological drugs
anifrolumab
Accesso online:https://rsp.mediar-press.net/rsp/article/view/3072
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi